Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain
Completed
- Conditions
- Rheumatoid ArthritisInflammation
- Registration Number
- NCT00195364
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
The purpose of this study is to evaluate long-term safety of etanercept in patients with rheumatoid arthritis who successfully have completed open-label safety study 0881A1-301-EU
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 93
Inclusion Criteria
- To have completed 0881A1-301-EU study in Spain
- Clinical diagnosis by ACR revised criteria of rheumatoid arthritis.
Exclusion Criteria
- Hypersensibility to etanercept or any of its components
- Significant concurrent medical disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of TNF-alpha inhibition by etanercept influence long-term safety in rheumatoid arthritis (NCT00195364)?
How does etanercept's long-term safety profile compare to standard-of-care DMARDs in rheumatoid arthritis patients (NCT00195364)?
Which biomarkers correlate with sustained efficacy or adverse events in etanercept-treated rheumatoid arthritis (NCT00195364)?
What are the long-term adverse event risks of etanercept in rheumatoid arthritis, particularly injection-site reactions or infections (NCT00195364)?
How do combination therapies of etanercept with methotrexate affect safety outcomes in rheumatoid arthritis compared to monotherapy (NCT00195364)?